UNSPSC 85562004: Revision of autologous tissue substitute in left ear, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to revision of autologous tissue substitute in left ear, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 09WJ37Z

UNSPSC 85562004 Revision of autologous tissue substitute in left ear, percutaneous approach is a Commodity code that shows no recent state and local procurement activity aligned with its nominal clinical scope. The six most-recent opportunities tagged to this code are soliciting occupational medical surveillance, disability medical evaluations, pharmacy benefit management, surgical benefit carve-outs, youth detention healthcare services, and temporary health professional staffing — none of which involve tissue substitutes, ear procedures, or autologous grafting. The code appears to be a medical procedure classification that state and local procurement offices have applied inconsistently or erroneously to health services RFPs that do not match the code's narrow clinical definition.

State and local buyers issuing under this code designation include county governments (Harris County Juvenile Probation Department, Collier County Board of County Commissioners, Santa Clara County Health System), municipal retirement boards (City of Phoenix Retirement Office), transit authorities (Washington State Department of Transportation), and municipal HR departments (City of Long Beach). Recent opportunities span Arizona, California, Florida, Texas, and Washington, with response windows clustered in September and October 2026. The mismatch between code designation and actual scope — combined with the absence of any ear-reconstruction or tissue-substitute procurement in the recent record — suggests this code is not a reliable or active procurement channel in state and local markets. Firms pursuing autologous tissue repair or similar clinical procedures should verify code assignments independently before investing in bid preparation under this designation.